MBI finds new home for stock
Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and
Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and stockholders equity of not less than $50 million. MBI was unable to meet this requirement, and was delisted on Jan. 4. The company began trading under the new symbol MBIO on NASDs (National Association of Securities Dealers) over-the-counter bulletin board on Jan. 5.
In November, San Diego-based MBI and Palatin Technologies of Princeton, NJ, signed an intent to merge (SCAN 11/24/99). The two firms are in discussions with the Securities and Exchange Commission and their stockholders, and hope to close the deal by April, according to Patricia Sullivan, spokesperson for MBI. If the merger is completed, the new firm will operate under Palatins name and will trade on AMEX.
In other MBI news, the company announced last month that Chugai Pharmaceuticals of Tokyo has paid MBI $2 million as Chugai starts clinical trials with Optison for assessment of left ventricular opacification and myocardial perfusion.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
